{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T12:31:19Z","timestamp":1785328279277,"version":"3.55.0"},"reference-count":46,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2027,3,20]],"date-time":"2027-03-20T00:00:00Z","timestamp":1805500800000},"content-version":"am","delay-in-days":384,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000897","name":"Cystic Fibrosis Foundation","doi-asserted-by":"publisher","award":["FLUME17AB0"],"award-info":[{"award-number":["FLUME17AB0"]}],"id":[{"id":"10.13039\/100000897","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000897","name":"Cystic Fibrosis Foundation","doi-asserted-by":"publisher","award":["WEST17AB0"],"award-info":[{"award-number":["WEST17AB0"]}],"id":[{"id":"10.13039\/100000897","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000897","name":"Cystic Fibrosis Foundation","doi-asserted-by":"publisher","award":["SANDER17AB0"],"award-info":[{"award-number":["SANDER17AB0"]}],"id":[{"id":"10.13039\/100000897","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000897","name":"Cystic Fibrosis Foundation","doi-asserted-by":"publisher","award":["HELTSH15A0"],"award-info":[{"award-number":["HELTSH15A0"]}],"id":[{"id":"10.13039\/100000897","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000897","name":"Cystic Fibrosis Foundation","doi-asserted-by":"publisher","award":["WEST15A0"],"award-info":[{"award-number":["WEST15A0"]}],"id":[{"id":"10.13039\/100000897","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000897","name":"Cystic Fibrosis Foundation","doi-asserted-by":"publisher","award":["SANDER14A0"],"award-info":[{"award-number":["SANDER14A0"]}],"id":[{"id":"10.13039\/100000897","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000897","name":"Cystic Fibrosis Foundation","doi-asserted-by":"publisher","award":["007084L124"],"award-info":[{"award-number":["007084L124"]}],"id":[{"id":"10.13039\/100000897","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000897","name":"Cystic Fibrosis Foundation","doi-asserted-by":"publisher","award":["GOSS15A0"],"award-info":[{"award-number":["GOSS15A0"]}],"id":[{"id":"10.13039\/100000897","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000897","name":"Cystic Fibrosis Foundation","doi-asserted-by":"publisher","award":["FLUME15A0"],"award-info":[{"award-number":["FLUME15A0"]}],"id":[{"id":"10.13039\/100000897","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000897","name":"Cystic Fibrosis Foundation","doi-asserted-by":"publisher","award":["WEST175Y"],"award-info":[{"award-number":["WEST175Y"]}],"id":[{"id":"10.13039\/100000897","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007812","name":"University of Washington","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007812","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006108","name":"National Center for Advancing Translational Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006108","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","cysticfibrosisjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Cystic Fibrosis"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.jcf.2025.12.007","type":"journal-article","created":{"date-parts":[[2025,12,12]],"date-time":"2025-12-12T04:44:32Z","timestamp":1765514672000},"page":"210-217","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Correlates of FEV\u2081 deficit in pulmonary exacerbations of cystic fibrosis and associated clinical outcomes"],"prefix":"10.1016","volume":"25","author":[{"given":"Oliver J.","family":"McElvaney","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonya L.","family":"Heltshe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6265-6249","authenticated-orcid":false,"given":"Don B.","family":"Sanders","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalie E.","family":"West","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbra","family":"Fogarty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5727-8164","authenticated-orcid":false,"given":"Donald R.","family":"VanDevanter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick A.","family":"Flume","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8602-0309","authenticated-orcid":false,"given":"Christopher H.","family":"Goss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jcf.2025.12.007_bib0001","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1136\/thx.2011.161117","article-title":"Exacerbation frequency and clinical outcomes in adult patients with cystic fibrosis","volume":"66","author":"de Boer","year":"2011","journal-title":"Thorax"},{"key":"10.1016\/j.jcf.2025.12.007_bib0002","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1164\/rccm.200812-1845PP","article-title":"Clinical Practice Guidelines for Pulmonary Therapies C. Cystic fibrosis pulmonary guidelines: treatment of pulmonary exacerbations","volume":"180","author":"Flume","year":"2009","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jcf.2025.12.007_bib0003","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1513\/AnnalsATS.201408-393OC","article-title":"A systematic review of factors associated with health-related quality of life in adolescents and adults with cystic fibrosis","volume":"12","author":"Habib","year":"2015","journal-title":"Ann Am Thorac Soc"},{"key":"10.1016\/j.jcf.2025.12.007_bib0004","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1183\/09031936.00159111","article-title":"Effect of pulmonary exacerbations on long-term lung function decline in cystic fibrosis","volume":"40","author":"Waters","year":"2012","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jcf.2025.12.007_bib0005","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1016\/j.jcf.2017.04.003","article-title":"Standardized Treatment of Pulmonary Exacerbations (STOP) study: Physician treatment practices and outcomes for individuals with cystic fibrosis with pulmonary Exacerbations","volume":"16","author":"West","year":"2017","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2025.12.007_bib0006","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1513\/AnnalsATS.202308-673OC","article-title":"Adjunctive systemic corticosteroids for pulmonary exacerbations of cystic fibrosis","volume":"21","author":"McElvaney","year":"2024","journal-title":"Ann Am Thorac Soc"},{"key":"10.1016\/j.jcf.2025.12.007_bib0007","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1055\/s-0042-1760250","article-title":"Diagnosis and management of cystic fibrosis exacerbations","volume":"44","author":"Milinic","year":"2023","journal-title":"Semin Respir Crit Care Med"},{"key":"10.1016\/j.jcf.2025.12.007_bib0008","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/j.jcf.2024.04.004","article-title":"Update on the diagnosis and management of cystic fibrosis pulmonary exacerbations","volume":"23","author":"Cogen","year":"2024","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2025.12.007_bib0009","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1080\/17476348.2019.1666715","article-title":"Targeting airway inflammation in cystic fibrosis","volume":"13","author":"McElvaney","year":"2019","journal-title":"Expert Rev Respir Med"},{"key":"10.1016\/j.jcf.2025.12.007_bib0010","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1164\/rccm.202102-0461OC","article-title":"A randomized clinical trial of antimicrobial duration for cystic fibrosis pulmonary exacerbation treatment","volume":"204","author":"Goss","year":"2021","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jcf.2025.12.007_bib0011","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.jcf.2017.06.002","article-title":"Recovery of lung function following a pulmonary exacerbation in patients with cystic fibrosis and the G551D-CFTR mutation treated with ivacaftor","volume":"17","author":"Flume","year":"2018","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2025.12.007_bib0012","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1136\/thoraxjnl-2014-206750","article-title":"Short-term and long-term response to pulmonary exacerbation treatment in cystic fibrosis","volume":"71","author":"Heltshe","year":"2016","journal-title":"Thorax"},{"key":"10.1016\/j.jcf.2025.12.007_bib0013","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1164\/rccm.200909-1421OC","article-title":"Failure to recover to baseline pulmonary function after cystic fibrosis pulmonary exacerbation","volume":"182","author":"Sanders","year":"2010","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jcf.2025.12.007_bib0014","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/j.jcf.2017.08.006","article-title":"A first step to STOP cystic fibrosis exacerbations","volume":"16","author":"Burgel","year":"2017","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2025.12.007_bib0015","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.cct.2017.11.012","article-title":"Study design considerations for the Standardized Treatment of Pulmonary Exacerbations 2 (STOP2): A trial to compare intravenous antibiotic treatment durations in CF","volume":"64","author":"Heltshe","year":"2018","journal-title":"Contemp Clin Trials"},{"key":"10.1016\/j.jcf.2025.12.007_bib0016","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1016\/j.jcf.2017.04.005","article-title":"Standardized Treatment of Pulmonary Exacerbations (STOP) study: observations at the initiation of intravenous antibiotics for cystic fibrosis pulmonary exacerbations","volume":"16","author":"Sanders","year":"2017","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2025.12.007_bib0017","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/j.jcf.2017.04.004","article-title":"Rationalizing endpoints for prospective studies of pulmonary exacerbation treatment response in cystic fibrosis","volume":"16","author":"VanDevanter","year":"2017","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2025.12.007_bib0018","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1016\/j.jcf.2019.05.009","article-title":"Correspondence between lung function and symptom measures from the Cystic Fibrosis Respiratory Symptom Diary\u2013Chronic Respiratory Infection Symptom Score (CFRSD-CRISS)","volume":"18","author":"Gold","year":"2019","journal-title":"J. Cyst. Fibros"},{"key":"10.1016\/j.jcf.2025.12.007_bib0019","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.jcf.2009.04.003","article-title":"Patient-reported respiratory symptoms in cystic fibrosis","volume":"8","author":"Goss","year":"2009","journal-title":"J Cyst Fibros"},{"issue":"Suppl 1","key":"10.1016\/j.jcf.2025.12.007_bib0020","doi-asserted-by":"crossref","first-page":"i42","DOI":"10.1136\/bmjqs-2013-002345","article-title":"Redesigning care to meet national recommendation of four or more yearly clinic visits in patients with cystic fibrosis","volume":"23","author":"Berlinski","year":"2014","journal-title":"BMJ Qual Saf"},{"key":"10.1016\/j.jcf.2025.12.007_bib0021","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1093\/aje\/kwj149","article-title":"Variable selection for propensity score models","volume":"163","author":"Brookhart","year":"2006","journal-title":"Am J Epidemiol"},{"key":"10.1016\/j.jcf.2025.12.007_bib0022","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1093\/biomet\/70.1.41","article-title":"The central role of the propensity score in observational studies for causal effects","volume":"70","author":"Rosenbaum","year":"1983","journal-title":"Biometrika"},{"key":"10.1016\/j.jcf.2025.12.007_bib0023","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1136\/thorax-2022-219943","article-title":"Effect of elexacaftor\/tezacaftor\/ivacaftor on airway and systemic inflammation in cystic fibrosis","volume":"78","author":"Casey","year":"2023","journal-title":"Thorax"},{"key":"10.1016\/j.jcf.2025.12.007_bib0024","doi-asserted-by":"crossref","first-page":"1818","DOI":"10.1513\/AnnalsATS.202111-1266OC","article-title":"Acute pulmonary exacerbation phenotypes in patients with cystic fibrosis","volume":"19","author":"Carter","year":"2022","journal-title":"Ann Am Thorac Soc"},{"key":"10.1016\/j.jcf.2025.12.007_bib0025","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/j.jcf.2022.12.013","article-title":"Pulmonary exacerbation inflammatory phenotypes in adults with cystic fibrosis","volume":"22","author":"Dong","year":"2023","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2025.12.007_bib0026","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1164\/rccm.201905-1013OC","article-title":"Specific inhibition of the NLRP3 inflammasome as an antiinflammatory strategy in cystic fibrosis","volume":"200","author":"McElvaney","year":"2019","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jcf.2025.12.007_bib0027","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aav4634","article-title":"CFTR-PTEN-dependent mitochondrial metabolic dysfunction promotes Pseudomonas aeruginosa airway infection","volume":"11","author":"Riquelme","year":"2019","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.jcf.2025.12.007_bib0028","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1038\/nm1690","article-title":"Cleavage of CXCR1 on neutrophils disables bacterial killing in cystic fibrosis lung disease","volume":"13","author":"Hartl","year":"2007","journal-title":"Nat Med"},{"key":"10.1016\/j.jcf.2025.12.007_bib0029","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1016\/j.cmet.2020.04.017","article-title":"Pseudomonas aeruginosa utilizes host-derived itaconate to redirect its metabolism to promote biofilm formation","volume":"31","author":"Riquelme","year":"2020","journal-title":"Cell Metab"},{"key":"10.1016\/j.jcf.2025.12.007_bib0030","doi-asserted-by":"crossref","first-page":"2145","DOI":"10.1001\/jama.2010.1665","article-title":"Infection with transmissible strains of Pseudomonas aeruginosa and clinical outcomes in adults with cystic fibrosis","volume":"304","author":"Aaron","year":"2010","journal-title":"JAMA"},{"key":"10.1016\/j.jcf.2025.12.007_bib0031","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1002\/ppul.10127","article-title":"Pseudomonas aeruginosa and other predictors of mortality and morbidity in young children with cystic fibrosis","volume":"34","author":"Emerson","year":"2002","journal-title":"Pediatr Pulmonol"},{"key":"10.1016\/j.jcf.2025.12.007_bib0032","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1183\/09031936.00166412","article-title":"Factors associated with FEV1 decline in cystic fibrosis: analysis of the ECFS patient registry","volume":"43","author":"Kerem","year":"2014","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jcf.2025.12.007_bib0033","series-title":"Treatment of pulmonary exacerbations of cystic fibrosis. Clinical practice guidelines for cystic fibrosis","year":"1997"},{"key":"10.1016\/j.jcf.2025.12.007_bib0034","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1016\/j.jcf.2023.02.006","article-title":"Re-examining baseline lung function recovery following IV-treated pulmonary exacerbations","volume":"22","author":"Heltshe","year":"2023","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2025.12.007_bib0035","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1513\/AnnalsATS.201608-615OC","article-title":"Scientific Advisory Group I, coordinators of the epidemiologic study of cystic F. Relationship of antibiotic treatment to recovery after acute FEV(1) decline in children with cystic fibrosis","volume":"14","author":"Morgan","year":"2017","journal-title":"Ann Am Thorac Soc"},{"key":"10.1016\/j.jcf.2025.12.007_bib0036","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1016\/j.jcf.2021.12.003","article-title":"C-reactive protein (CRP) as a biomarker of pulmonary exacerbation presentation and treatment response","volume":"21","author":"VanDevanter","year":"2022","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2025.12.007_bib0037","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1164\/rccm.202005-1583OC","article-title":"Characterization of the inflammatory response to severe COVID-19 illness","volume":"202","author":"McElvaney","year":"2020","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jcf.2025.12.007_bib0038","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1164\/rccm.201709-1954LE","article-title":"Glycosylation repurposes alpha-1 antitrypsin for resolution of community-acquired pneumonia","volume":"197","author":"McCarthy","year":"2018","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jcf.2025.12.007_bib0039","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1016\/S0140-6736(21)00676-0","article-title":"Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial","volume":"397","author":"Group","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.jcf.2025.12.007_bib0040","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1056\/NEJMoa1803185","article-title":"C-reactive protein testing to guide antibiotic prescribing for COPD exacerbations","volume":"381","author":"Butler","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jcf.2025.12.007_bib0041","doi-asserted-by":"crossref","first-page":"2160","DOI":"10.1001\/jama.2020.6348","article-title":"Effect of C-reactive protein\u2013guided antibiotic treatment duration, 7-day treatment, or 14-day treatment on 30-day clinical failure rate in patients with uncomplicated gram-negative bacteremia: a randomized clinical trial","volume":"323","author":"von Dach","year":"2020","journal-title":"JAMA"},{"key":"10.1016\/j.jcf.2025.12.007_bib0042","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1056\/NEJMoa2411664","article-title":"Phase 3 trial of the DPP-1 inhibitor brensocatib in bronchiectasis","volume":"392","author":"Chalmers","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jcf.2025.12.007_bib0043","doi-asserted-by":"crossref","first-page":"2127","DOI":"10.1056\/NEJMoa2021713","article-title":"Phase 2 trial of the DPP-1 inhibitor brensocatib in bronchiectasis","volume":"383","author":"Chalmers","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jcf.2025.12.007_bib0044","doi-asserted-by":"crossref","first-page":"2013","DOI":"10.1056\/NEJMoa1709846","article-title":"Tezacaftor-ivacaftor in patients with cystic fibrosis homozygous for Phe508del","volume":"377","author":"Taylor-Cousar","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jcf.2025.12.007_bib0045","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1056\/NEJMoa1409547","article-title":"Lumacaftor-ivacaftor in patients with cystic fibrosis homozygous for Phe508del CFTR","volume":"373","author":"Wainwright","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jcf.2025.12.007_bib0046","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1016\/j.jcf.2023.06.012","article-title":"Impact of lumacaftor\/ivacaftor and tezacaftor\/ivacaftor on treatment response in pulmonary exacerbations of F508del\/F508del cystic fibrosis","volume":"22","author":"McElvaney","year":"2023","journal-title":"J Cyst Fibros"}],"container-title":["Journal of Cystic Fibrosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S156919932502538X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S156919932502538X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T11:37:48Z","timestamp":1781782668000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S156919932502538X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":46,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["S156919932502538X"],"URL":"https:\/\/doi.org\/10.1016\/j.jcf.2025.12.007","relation":{},"ISSN":["1569-1993"],"issn-type":[{"value":"1569-1993","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Correlates of FEV\u2081 deficit in pulmonary exacerbations of cystic fibrosis and associated clinical outcomes","name":"articletitle","label":"Article Title"},{"value":"Journal of Cystic Fibrosis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcf.2025.12.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}